Mylan earmarks €380m for Irish expansion
pharmafile | April 24, 2012 | News story | Manufacturing and Production | Galway, Ireland, Mylan, manufacturing and production
Generic drugmaker Mylan has announced a plan to invest €380 million in its operations in the Republic of Ireland, including its manufacturing and R&D operations in Dublin and Galway.
The investment is designed to bolster the company’s respiratory and injectables capabilities, which chief executive Heather Bresch said are among the firm’s long-term growth drivers, as well as oral solid dose capacity.
Around 220 of the new jobs will be based in Galway, the location of Mylan’s specialty injectables subsidiary Bioniche Pharma and the primary site for the firm’s manufacturing and packaging facilities. The remainder will be located at its Gerard Laboratories unit in north Dublin, which produces more than 180 different inhaled and oral dose product lines.
The ramp up in worker numbers in Ireland spans the firm’s R&D and manufacturing operations and is considerable, given that Mylan currently employs around 700 people across the country.
The €76 million-a-year expansion is being supported by IDA Ireland and Udaras Na Gaeltachta, a regional economic development agency that provides specialised support for Irish-speaking communities.
“Ireland has proven to be a valuable location for Mylan, providing the company with access to a skilled and highly educated workforce that shares our strong work ethic and commitment to excellence,” said Bresch.
The generic drugmaker has shrugged off the tough operating environment for pharmaceutical manufacturers in recent years with a period of solid growth, with sales topping $6 billion in 2011. The company is also planning to expand in India during 2012.
– Meanwhile, Diaceutics, a firm specialising in software applications for personalised medicines, has announced plans to create 20 new jobs in Ireland over the next three years through the setting up of a unit at the Dundalk Institute of Technology in County Louth. The unit will focus on the further development of Diaceutics’ Fusion software, a web-based application that provides a range of business intelligence and performance management applications used for personalised medicine planning, collaboration and decision-making.
Phil Taylor
Related Content
Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …
Astellas plans to invest over €330m in new facility in Ireland
Astellas Pharma has announced that it is preparing to submit a planning application to build …
Pfizer to pay $345 million in EpiPen lawsuit
Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …
